4
Changes in Ownership
Cytek Biosciences, Inc. Filed Acc 0001209191-23-031260
Chief Commercial Officer gave up 3,757 shares (to pay taxes)
- Chief Commercial Officer acquired 9,644 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Option exercise | +7,804 | 7,804 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Shares withheld for taxes | −3,040 | $6.69 | $20,338 | 4,764 | D |
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Option exercise | +1,840 | 6,604 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Shares withheld for taxes | −717 | $6.69 | $4,797 | 5,887 | D |
| Derivatives | |||||||
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Option exercise · Restricted Stock Units | −7,804 | 23,413 | D | ||
| Garland Jonathan Todd Chief Commercial Officer | 2023-05-18 | Option exercise · Restricted Stock Units | −1,840 | 42,340 | D | ||
Loading xslF345X04/doc4.xml…